According to Junshi Biotech's announcement, it achieved revenue of 1,696 billion yuan in the first half of 2026, an increase of about 45.18% over the previous year, mainly due to an increase in drug sales revenue; of these, domestic sales revenue of treprilizumab was about 1,299 billion yuan, an increase of about 36% over the previous year. More than 700 people were enrolled in the clinical study during the reporting period, 5 products were in phase III clinical trials, and 2 were in the NDA acceptance stage; treprilimab has been approved for marketing in more than 50 countries and regions, and commercialization cooperation has been reached with partners in over 80 countries. By the end of the reporting period, a total of 202 patents had been authorized, and 9 new patents were added during the reporting period. Chairman Xiong Jun increased his holdings of the company by 3.259,500 shares from April 12, 2025 to March 31, 2026, accounting for 0.32% of the total share capital, and a cumulative total turnover of about 101 million yuan.

According to Junshi Biotech's announcement, it achieved revenue of 1,696 billion yuan in the first half of 2026, an increase of about 45.18% over the previous year, mainly due to an increase in drug sales revenue; of these, domestic sales revenue of treprilizumab was about 1,299 billion yuan, an increase of about 36% over the previous year. More than 700 people were enrolled in the clinical study during the reporting period, 5 products were in phase III clinical trials, and 2 were in the NDA acceptance stage; treprilimab has been approved for marketing in more than 50 countries and regions, and commercialization cooperation has been reached with partners in over 80 countries. By the end of the reporting period, a total of 202 patents had been authorized, and 9 new patents were added during the reporting period. Chairman Xiong Jun increased his holdings of the company by 3.259,500 shares from April 12, 2025 to March 31, 2026, accounting for 0.32% of the total share capital, and a cumulative total turnover of about 101 million yuan.